Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Martin

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Marital status and survival in patients with cancerAyal A Aizer, Ming-Hui Chen, Ellen P McCarthy, et al.
Journal of the National Cancer Institute|February 12, 2026
Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapySarah L Kerns, Paul C Dinh, Patrick O Monahan, et al.
The Journal of Urology|April 14, 2012
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortalityYolanda D Tseng, Ming-Hui Chen, Clair J Beard, et al.
International Journal of Radiation Oncology, Biology, Physics|November 5, 2015
Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed PatientsVinayak Muralidhar, Ming-Hui Chen, Gally Reznor, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
European Urology|December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Brachytherapy|August 17, 2016
Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancerYu-Wei Chen, Vinayak Muralidhar, Brandon A Mahal, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 14, 2021
Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional StudyShirin ArdeshirRouhaniFard, Paul C Dinh, Patrick O Monahan, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Marital status and survival in patients with cancerAyal A Aizer, Ming-Hui Chen, Ellen P McCarthy, et al.
Journal of the National Cancer Institute|February 12, 2026
Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapySarah L Kerns, Paul C Dinh, Patrick O Monahan, et al.
The Journal of Urology|April 14, 2012
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortalityYolanda D Tseng, Ming-Hui Chen, Clair J Beard, et al.
International Journal of Radiation Oncology, Biology, Physics|November 5, 2015
Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed PatientsVinayak Muralidhar, Ming-Hui Chen, Gally Reznor, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
European Urology|December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Brachytherapy|August 17, 2016
Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancerYu-Wei Chen, Vinayak Muralidhar, Brandon A Mahal, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 14, 2021
Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional StudyShirin ArdeshirRouhaniFard, Paul C Dinh, Patrick O Monahan, et al.
Pageof 13